<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36739118</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2173-5743</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Reumatologia clinica</Title><ISOAbbreviation>Reumatol Clin (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Systemic lupus erythematosus myocarditis after COVID-19 vaccination.</ArticleTitle><Pagination><StartPage>114</StartPage><EndPage>116</EndPage><MedlinePgn>114-116</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.reumae.2022.06.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2173-5743(23)00012-6</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Cases of acute myocarditis have been after administration of the BNT162b2 and Ad26.COV2.S vaccine.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Describe another possible mechanism of myocarditis after COVID-19 vaccination.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">We describe the clinical case of a 72-year-old female with pleuritic chest pain one week after the third of the BNT162b2 mRNA vaccine. Serological tests for cardiotropic pathogens were negative, and autoimmunity screening was positive with anti-nuclear antibody (ANA) in 1:160 dilution, Anti-double-stranded DNA (anti-dsDNA), and anti-histone antibodies. <sup>18</sup>F-fluoro-deoxy-glucose (FDG) positron emission tomography/computed tomography (PET/CT) showed a focal myocardial and pericardial inflammatory process in the cardiac apex.</AbstractText><AbstractText Label="RESULTS AND DISCUSSION" NlmCategory="CONCLUSIONS">Systemic lupus erythematosus (SLE) diagnosis was made with myocardial affection. As far as we know, this is the first report of a case of lupus myocarditis after the COVID-19 vaccine.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Given the pathogenic rationales, the association between SLE and myocarditis should be considered.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Espa&#xf1;a, S.L.U. and Sociedad Espa&#xf1;ola de Reumatolog&#xed;a y Colegio Mexicano de Reumatolog&#xed;a. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sogbe</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Internal Medicine Department, Cl&#xed;nica Universidad de Navarra, Pamplona, Spain. Electronic address: msogbe@unav.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blanco-Di Matteo</LastName><ForeName>Andr&#xe9;s</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Internal Medicine Department, Cl&#xed;nica Universidad de Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Frisco</LastName><ForeName>I Madeleine</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Pulmonary Medicine Department, Cl&#xed;nica Universidad de Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bastidas</LastName><ForeName>Juan Fernando</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Nuclear Medicine Department, Cl&#xed;nica Universidad de Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salterain</LastName><ForeName>Nahikari</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Cl&#xed;nica Universidad de Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gavira</LastName><ForeName>Juan Jos&#xe9;</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Cl&#xed;nica Universidad de Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Reumatol Clin (Engl Ed)</MedlineTA><NlmUniqueID>101717526</NlmUniqueID><ISSNLinking>2173-5743</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>JT2NS6183B</RegistryNumber><NameOfSubstance UI="D000090984">Ad26COVS1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090982">BNT162 Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090984" MajorTopicYN="N">Ad26COVS1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000974" MajorTopicYN="N">Antibodies, Antinuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090982" MajorTopicYN="N">BNT162 Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009205" MajorTopicYN="Y">Myocarditis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072078" MajorTopicYN="N">Positron Emission Tomography Computed Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="INTRODUCCI&#xd3;N">Se han presentado casos de miocarditis aguda tras la administraci&#xf3;n de las vacunas BNT162b2 y Ad26.COV2.S.</AbstractText><AbstractText Label="OBJETIVO">Describir otro posible mecanismo de miocarditis posterior a la vacunaci&#xf3;n contra el COVID-19.</AbstractText><AbstractText Label="PRESENTACI&#xd3;N DEL CASO">Describimos el caso cl&#xed;nico de una mujer de 72 a&#xf1;os con dolor tor&#xe1;cico pleur&#xed;tico una semana despu&#xe9;s de la tercera vacuna de ARNm BNT162b2. Las pruebas serol&#xf3;gicas para pat&#xf3;genos cardiotr&#xf3;pos fueron negativas y el cribado de autoinmunidad fue positivo con anticuerpos antinucleares (ANA) en diluci&#xf3;n 1:160, anticuerpos anti-ADN de doble cadena (anti-dsADN) y antihistonas. La tomograf&#xed;a por emisi&#xf3;n de positrones/tomograf&#xed;a computarizada (PET/TC) con <sup>18</sup>F-fluorodesoxiglucosa (FDG) mostr&#xf3; un proceso inflamatorio mioc&#xe1;rdico y peric&#xe1;rdico focal en el &#xe1;pex card&#xed;aco.</AbstractText><AbstractText Label="RESULTADOS Y DISCUSI&#xd3;N">Se realiz&#xf3; el diagn&#xf3;stico de lupus eritematoso sist&#xe9;mico (LES) con afectaci&#xf3;n mioc&#xe1;rdica. Hasta donde sabemos, este es el primer reporte de un caso de miocarditis l&#xfa;pica despu&#xe9;s de la vacuna contra el COVID-19.</AbstractText><AbstractText Label="CONCLUSI&#xd3;N">Dadas las justificaciones patog&#xe9;nicas, se debe considerar la asociaci&#xf3;n entre lupus eritematoso sist&#xe9;mico (LES) y miocarditis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Espa&#xf1;a, S.L.U. and Sociedad Espa&#xf1;ola de Reumatolog&#xed;a y Colegio Mexicano de Reumatolog&#xed;a. All rights reserved.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ARN mensajero BNT162B2</Keyword><Keyword MajorTopicYN="N">BNT162B2 messenger RNA</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccination</Keyword><Keyword MajorTopicYN="N">Lupus eritematoso sist&#xe9;mico</Keyword><Keyword MajorTopicYN="N">Miocarditis</Keyword><Keyword MajorTopicYN="N">Myocarditis</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">Vacunaci&#xf3;n COVID-19</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>4</Day><Hour>20</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36739118</ArticleId><ArticleId IdType="pmc">PMC9892927</ArticleId><ArticleId IdType="doi">10.1016/j.reumae.2022.06.006</ArticleId><ArticleId IdType="pii">S2173-5743(23)00012-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen Y., Xu Z., Wang P., Li X.M., Shuai Z.W., Ye D.Q., et al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 2022;165:386&#x2013;391. doi: 10.1111/imm.13443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13443</ArticleId><ArticleId IdType="pubmed">34957554</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara L.J., Vera-Lastra O., Mahroum N., Pineda C., Shoenfeld Y. Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune/inflammatory syndrome expand? Clin Rheumatol. 2022;41:1603&#x2013;1609. doi: 10.1007/s10067-022-06149-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06149-4</ArticleId><ArticleId IdType="pmc">PMC8979721</ArticleId><ArticleId IdType="pubmed">35378658</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M., Costenbader K., Daikh D., Brinks R., Mosca M., Ramsey-Goldman R., et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78:1151&#x2013;1159. doi: 10.1136/annrheumdis-2018-214819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214819</ArticleId><ArticleId IdType="pubmed">31383717</ArticleId></ArticleIdList></Reference><Reference><Citation>Heymans S., Cooper L.T. Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms. Nat Rev Cardiol. 2022;19:75&#x2013;77. doi: 10.1038/s41569-021-00662-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-021-00662-w</ArticleId><ArticleId IdType="pmc">PMC8656440</ArticleId><ArticleId IdType="pubmed">34887571</ArticleId></ArticleIdList></Reference><Reference><Citation>Mevorach D., Anis E., Cedar N., Bromberg M., Haas E.J., Nadir E., et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J Med. 2021;385:2140&#x2013;2149. doi: 10.1056/NEJMoa2109730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2109730</ArticleId><ArticleId IdType="pmc">PMC8531987</ArticleId><ArticleId IdType="pubmed">34614328</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotzin B.L. Systemic lupus erythematosus. Cell. 1996;85:303&#x2013;306. doi: 10.1016/s0092-8674(00)81108-36.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0092-8674(00)81108-36</ArticleId><ArticleId IdType="pubmed">8616885</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil S., Patil A. Systemic lupus erythematosus after COVID-19 vaccination: a case report. J Cosmet Dermatol. 2021;20:3103&#x2013;3104. doi: 10.1111/jocd.14386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocd.14386</ArticleId><ArticleId IdType="pmc">PMC8661983</ArticleId><ArticleId IdType="pubmed">34418261</ArticleId></ArticleIdList></Reference><Reference><Citation>Zavala-Miranda M.F., Gonz&#xe1;lez-Ibarra S.G., P&#xe9;rez-Arias A.A., Uribe-Uribe N.O., Mejia-Vilet J.M. New-onset systemic lupus erythematosus beginning as class V lupus nephritis after COVID-19 vaccination. Kidney Int. 2021;100:1340&#x2013;1341. doi: 10.1016/j.kint.2021.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.09.009</ArticleId><ArticleId IdType="pmc">PMC8455236</ArticleId><ArticleId IdType="pubmed">34560139</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>